Frontiers in Cardiovascular Medicine, Journal Year: 2022, Volume and Issue: 9
Published: Aug. 8, 2022
Hypertension (HTN) is a common comorbidity in non-alcoholic fatty liver disease (NAFLD) affecting up to 40% of individuals. However, the impact HTN and its control on outcomes NAFLD remains unclear. Therefore, we aimed examine survival longitudinal cohort patients.
Language: Английский
Acta Pharmacologica Sinica, Journal Year: 2022, Volume and Issue: 43(5), P. 1103 - 1119
Published: Feb. 25, 2022
Language: Английский
Citations
77
PLoS ONE, Journal Year: 2022, Volume and Issue: 17(2), P. e0263931 - e0263931
Published: Feb. 17, 2022
Non-alcoholic fatty liver disease is a condition that increasing worldwide and expected to become the number one cause of cirrhosis hepatocellular carcinoma in next 5 years. Currently there are no successful or approved pharmacological treatments. Weight loss first-line therapy as 7 10% reduction improves steatosis, inflammation, hepatocyte ballooning, fibrosis. To achieve this, lifestyle interventions including daily exercise diet must be encouraged. We aimed assess effects diet, exercise, combination both compared conventional treatment patients with non-alcoholic disease.
Language: Английский
Citations
73
Diabetes Obesity and Metabolism, Journal Year: 2022, Volume and Issue: 25(1), P. 3 - 17
Published: Aug. 5, 2022
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States as an adjunct to diet and exercise improve glycaemic control adults with type 2 diabetes under investigation for use chronic weight management, major adverse cardiovascular events management of other conditions, including heart failure preserved ejection fraction obesity non-cirrhotic non-alcoholic steatohepatitis. The Phase 3 SURPASS 1-5 clinical trial programme was designed assess efficacy safety once-weekly subcutaneously injected tirzepatide (5, 10 15 mg), monotherapy or combination therapy, across broad spectrum people diabetes. Use studies associated marked reductions glycated haemoglobin (-1.87 -2.59%, -20 -28 mmol/mol) body (-6.2 -12.9 kg), well parameters commonly heightened cardiometabolic risk such blood pressure, visceral adiposity circulating triglycerides. In SUPRASS-2, these were greater than GLP-1 semaglutide mg. tolerated, low hypoglycaemia when used without insulin secretagogues showed generally similar profile class. Accordingly, evidence from trials suggests that offers new opportunity effective lowering
Language: Английский
Citations
71
Cellular and Molecular Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 15(6), P. 1311 - 1324
Published: Jan. 1, 2023
Nonalcoholic fatty liver disease (NAFLD) is the manifestation of metabolic syndrome. NAFLD constitutes a spectrum pathologies ranging from simple hepatic steatosis (nonalcoholic liver) to more progressive form steatohepatitis and fibrosis, which can culminate in cirrhosis hepatocellular carcinoma. Macrophages play multiple roles context pathogenesis by regulating inflammatory responses homeostasis thereby may represent an attractive therapeutic target. Advances high-resolution methods have highlighted extraordinary heterogeneity plasticity macrophage populations activation states thereof. Harmful/disease-promoting as well beneficial/restorative phenotypes co-exist are dynamically regulated, thus this complexity must be taken into consideration strategies concerning targeting. Macrophage includes their distinct ontogeny (embryonic Kupffer cells vs bone marrow-/monocyte-derived macrophages) functional phenotype, for example, phagocytes, lipid- scar-associated macrophages, or restorative macrophages. Here, we discuss multifaceted role macrophages steatosis, steatohepatitis, transition fibrosis carcinoma, focusing on both beneficial maladaptive functions at different stages. We also highlight systemic aspect dysregulation illustrate contribution reciprocal crosstalk between organs compartments (eg, gut-liver axis, adipose tissue, cardiohepatic interactions). Furthermore, current state development pharmacologic treatment options targeting biology.
Language: Английский
Citations
46
Hepatology Communications, Journal Year: 2023, Volume and Issue: 7(4)
Published: March 30, 2023
Background and Aims: We present findings from the inaugural American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable, which was convened to evaluate evidence for physical activity as a means preventing or modifying course NAFLD. Approach Results: A scoping review conducted map scientific literature identify key concepts, research gaps, available inform clinical practice, policymaking, research. The demonstrated regular is associated with decreased risk NAFLD development. Low greater disease progression extrahepatic cancer. During routine health care visits, all patients should be screened counseled about benefits, including reduction in liver fat improvement body composition, fitness, quality life. While most benefits occur without clinically significant weight loss, remains limited regarding association between fibrosis. At least 150 min/wk moderate 75 vigorous-intensity are recommended If formal exercise training program prescribed, aerobic addition resistance preferred. Conclusions: panel found consistent compelling that plays an important role improving intermediate outcomes. Health care, public professionals strongly encouraged disseminate information this report. Future prioritize determining optimal strategies promoting among individuals at those already diagnosed
Language: Английский
Citations
44
Metabolism, Journal Year: 2024, Volume and Issue: 161, P. 156028 - 156028
Published: Sept. 11, 2024
Language: Английский
Citations
23
Diabetes Spectrum, Journal Year: 2024, Volume and Issue: 37(1), P. 9 - 19
Published: Feb. 1, 2024
The prevalence of nonalcoholic fatty liver disease (NAFLD) in the United States is 38%, having increased by 50% within past 3 decades. estimated NAFLD among people with type 2 diabetes 55–70%. presence associated a higher likelihood progression to fibrosis development, transplant, and death. Cardiovascular main cause mortality NAFLD, risk death significantly both diabetes. carries high patient economic burdens but low awareness general public health care providers. This article reviews epidemiology discusses need for appropriate stratification, referral specialty care, management cardiometabolic factors, treatment disease. authors present call action raise address its increasing burden systematic efficient manner.
Language: Английский
Citations
19
Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(2), P. 207 - 217
Published: March 18, 2024
Language: Английский
Citations
19
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(1), P. 306 - 306
Published: Jan. 1, 2025
Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated (MAFLD), is the most prevalent worldwide. It associated with an increased risk of developing hepatocellular carcinoma (HCC) in background cirrhosis or without cirrhosis. The prevalence NAFLD-related HCC increasing all over globe, and surveillance NAFLD cases not that common. In present review, we attempt to summarize promising treatments clinical trials focused on NAFLD, nonalcoholic steatohepatitis (NASH), past five seven years. We categorized based type intervention. Most are still running, only a few completed conclusive results. trial NCT03942822, 25 mg/day milled chia seeds improved condition. Completed NCT03524365 concluded Rouxen-Y gastric bypass (RYGB) sleeve gastrectomy (SG) results histological resolution NASH worsening fibrosis, while NCT04677101 validated sensitivity/accuracy blood biomarkers predicting fibrosis stage. Moreover, empagliflozin (NCT05694923), curcuvail (NCT06256926), obeticholic acid (NCT03439254) were but did provide However, NCT03900429 reported effective improvement by at least one stage, activity score (NAS), as well lipid profile patients 80 100 mg MGL-3196 (resmetirom). Funded Madrigal Pharmaceuticals, Rezdiffra (resmetirom), used NCT03900429, first FDA-approved drug for treatment NAFLD/NASH.
Language: Английский
Citations
4
Annals of Translational Medicine, Journal Year: 2021, Volume and Issue: 9(8), P. 729 - 729
Published: April 1, 2021
Abstract: Liver fibrosis is the excessive expression and accumulation of extracellular matrix proteins in liver. Fibrotic scarring occurs as consequence chronic injury inflammation. While successful treatment hepatitis B C reduced burden liver disease related to viral hepatitis, non-alcoholic fatty (NAFLD) or steatohepatitis (NASH) are nowadays leading causes hepatic worldwide. Although basic research activities have significantly advanced our understanding molecular pathogenesis, present therapeutic options for still limited. In stages, transplantation often remains only curative treatment. This highlights necessity preventive strategies avoid complications fibrosis, particularly cirrhosis, portal hypertension cancer. Lifestyle modifications (weight loss, exercise, healthy diet) basis prevention NAFLD-associated fibrosis. review, we discuss recent advances antifibrotic therapy. particular, review current concepts drug candidates NAFLD NASH. some compounds aim at reverting pathogenic metabolism, an alternative approach disconnect (e.g., NAFLD) from inflammation and/or Investigational drugs typically target metabolic pathways, insulin resistance, hepatocyte death, inflammatory cell recruitment activation, gut-liver axis, turnover. several promising failed phase 2 3 clinical trials (including elafibranor, emricasan selonsertib), results with farnesoid X receptor agonist obeticholic acid, pan-PPAR lanifibranor chemokine CCR2/CCR5 inhibitor cenicriviroc support expectation effective pharmacological therapy near future. Tackling different directions by combinatorial lifestyle changes hold greatest prospects.
Language: Английский
Citations
102